YOLFTbeta
14

Mezzion Pharma Co.Ltd

140410 · KQ · Healthcare / Pharmaceuticals

66,400.00KRW-1600.00 (-2.35%)

Price History

Full chart

Market Stats

Previous Close68,000.00
Open68,000.00
Day Range65,900.00 – 69,200.00
52-Week Range45,850.00 – 179,900.00
Volume98.59K
Market Cap2.00T
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.76
50-Day Avg66,060.00
200-Day Avg82,369.00

About

Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOMr. Dong-Hyun Park
  • Employees44
  • HeadquartersC&H Building, Seoul, South Korea, Korea
  • Websitehttps://www.mezzion.co.kr

Leadership

  • Mr. Dong-Hyun ParkChairman, CEO & Pres · b. 1956
  • Moo-Hi YooChief Scientific Officer · b. 1952
  • Mr. William BreitenbachChief Commercial Officer

Financials

Income Statement

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.59B14.93B8.75B5.59B19.09B18.93B28.63B26.65B30.73B31.72B8.61B7.91B
Growth (%)-+73.72%-41.37%-36.17%+241.71%-0.82%+51.26%-6.92%+15.28%+3.24%-72.85%-8.15%
Cost of Revenue05.10B3.79B4.69B15.85B15.84B21.20B22.96B31.04B27.84B6.70B6.46B
Gross Profit8.59B9.83B4.96B898.62M3.24B3.10B7.44B3.70B-313.44M3.88B1.91B1.45B
Gross Margin100.00%65.85%56.72%16.09%16.96%16.35%25.98%13.88%-1.02%12.25%22.18%18.36%
Operating Expense6.91B12.93B12.60B17.78B25.17B27.76B14.97B20.50B23.02B18.22B16.21B18.22B
Operating Income1.68B-3.10B-7.64B-16.89B-21.93B-24.66B-7.53B-16.80B-23.33B-14.34B-14.30B-16.77B
Operating Margin19.56%-20.78%-87.29%-302.30%-114.89%-130.29%-26.30%-63.02%-75.93%-45.20%-166.05%-212.00%
EBITDA---------33.83B-10.62B-13.28B-36.28B
EBITDA Margin---------110.09%-33.47%-154.15%-458.66%
Net Income2.38B4.22B-12.98B-14.88B-18.88B-23.25B-13.83B-13.60B-36.30B-12.73B-19.48B-34.93B
Net Income Margin27.75%28.29%-148.38%-266.42%-98.89%-122.82%-48.30%-51.03%-118.13%-40.13%-226.17%-441.61%
R&D2.38B2.38B7.00B11.09B11.55B-937.56M1.96B2.22B938.97M294.04M1.26B
R&D as % of Total Revenue27.66%15.92%79.99%198.59%60.51%-3.27%7.34%7.22%2.96%3.41%15.92%
Interest Expense000000320.21M323.41M423.44M315.46M300.79M1.57B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%1.12%1.21%1.38%0.99%3.49%19.87%

Balance Sheet

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets67.30B103.05B95.90B74.04B75.06B58.87B75.63B83.93B54.02B92.15B74.00B98.02B
Total Liabilities3.97B40.52B43.09B20.87B17.74B16.04B18.82B21.14B27.78B30.70B27.94B80.83B
Total Equity63.34B62.54B52.81B53.17B57.32B42.83B56.81B62.79B26.24B61.44B46.06B17.19B
Cash20.11B61.94B15.81B23.62B19.48B11.20B33.95B1.79M1.46M40.25B607.00K25.57B
Total Debt-50.47B52.51B--2.84B4.09B-----

Cash Flow

Currency: KRW2012-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.14B1.77B-6.08B-13.21B-21.72B-20.88B-7.38B-15.07B-12.07B-11.02B-18.49B-16.59B
Investing Cash Flow-26.57B-977.88M-36.81B36.42B1.29B304.47M3.56B-16.33B17.41B-25.56B-9.58B-
Financing Cash Flow32.90B24.95B-1.80B-11.25B18.06B6.76B24.01B19.11B-615.79M47.21B670.32M-
Capital Expenditure564.10M564.10M169.02M719.85M572.07M1.10B774.25M357.81M1.76B11.86B13.48B13.27B
Free Cash Flow-------15.33B-21.25B-13.84B-22.88B-31.97B-29.86B
FCF to OCF------207.86%141.02%114.58%207.57%172.90%180.01%

Earnings

Report DateMar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Dec 3, 2014Feb 25, 2015Jun 3, 2015Aug 13, 2015Nov 17, 2015Feb 4, 2016May 16, 2016Aug 16, 2016Nov 14, 2016Feb 17, 2017May 16, 2017Aug 15, 2017Nov 14, 2017Feb 13, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 25, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 30, 2020May 15, 2020Aug 14, 2020Nov 15, 2020May 17, 2021Aug 17, 2021Nov 11, 2021Feb 18, 2022May 11, 2022Aug 12, 2022Nov 11, 2022Mar 16, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 18, 2024May 15, 2024Aug 13, 2024Nov 12, 2024Mar 17, 2025May 15, 2025Aug 11, 2025Nov 12, 2025Mar 16, 2026May 13, 2026Jun 30, 2026
EPS Estimate---------------------------------------------------------
EPS Actual3.08111.00-11.791.1411.336.05-41.67-13.89-27.07-50.09-25.96-12.62158.83-24.02188.51-141.61-101.05-214.40-213.74-60.36-221.34-21.49-77.40-346.33-128.06-322.66-1404.31-477.00-154.89-168.63-127.53-1328.68-119.00-220.00-224.33-83.67-123.00-60.00-243.03-243.01-604.1969.00-675.50-93.42-107.38-33.12-214.302.37-54.52-212.80-387.10-110.41-61.72-171.06-811.51-174.66248.06
Surprise---------------------------------------------------------
Timing-------------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap2.00T
Enterprise Value2.06T
Trailing P/E0.00
Forward P/E0.00
Price / Sales247.74
Price / Book53.38
Revenue (TTM)30.22B
Gross Profit (TTM)3.70B
EBITDA-19.33B
Profit Margin-81.66%
Operating Margin-69.31%
Return on Equity-4526.04%
Return on Assets-20.29%
Shares Outstanding8.55M
Shares Float20.83M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20121×
8.33Dec 27, 2012

Stock Splits

  • Apr 5, 2022959692:319897